USA - NASDAQ:ELTX - US28657F1030 - Common Stock
The current stock price of ELTX is 10.85 USD. In the past month the price increased by 4.24%. In the past year, price increased by 113.83%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.64 | 386.06B | ||
AMGN | AMGEN INC | 12.43 | 145.99B | ||
GILD | GILEAD SCIENCES INC | 14.34 | 137.72B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 97.91B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
REGN | REGENERON PHARMACEUTICALS | 12.17 | 58.88B | ||
ARGX | ARGENX SE - ADR | 76.71 | 43.52B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.75 | 39.08B | ||
INSM | INSMED INC | N/A | 28.66B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
NTRA | NATERA INC | N/A | 22.46B | ||
BIIB | BIOGEN INC | 8.47 | 19.89B |
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
ELICIO THERAPEUTICS INC
451 D Street, 5Th Floor
Boston MASSACHUSETTS US
Employees: 32
Phone: 18572090050
The current stock price of ELTX is 10.85 USD. The price decreased by -1.81% in the last trading session.
The exchange symbol of ELICIO THERAPEUTICS INC is ELTX and it is listed on the Nasdaq exchange.
ELTX stock is listed on the Nasdaq exchange.
8 analysts have analysed ELTX and the average price target is 12.75 USD. This implies a price increase of 17.51% is expected in the next year compared to the current price of 10.85. Check the ELICIO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELICIO THERAPEUTICS INC (ELTX) has a market capitalization of 177.29M USD. This makes ELTX a Micro Cap stock.
ELICIO THERAPEUTICS INC (ELTX) currently has 32 employees.
ELICIO THERAPEUTICS INC (ELTX) has a support level at 10.59 and a resistance level at 11.8. Check the full technical report for a detailed analysis of ELTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELTX does not pay a dividend.
ELICIO THERAPEUTICS INC (ELTX) will report earnings on 2025-11-11.
ELICIO THERAPEUTICS INC (ELTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.94).
The outstanding short interest for ELICIO THERAPEUTICS INC (ELTX) is 4.99% of its float. Check the ownership tab for more information on the ELTX short interest.
ChartMill assigns a technical rating of 10 / 10 to ELTX. When comparing the yearly performance of all stocks, ELTX is one of the better performing stocks in the market, outperforming 94.73% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ELTX. ELTX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ELTX reported a non-GAAP Earnings per Share(EPS) of -3.94. The EPS increased by 18.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -184.95% | ||
ROE | -2977.75% | ||
Debt/Equity | 5.09 |
8 analysts have analysed ELTX and the average price target is 12.75 USD. This implies a price increase of 17.51% is expected in the next year compared to the current price of 10.85.